Antibody

18개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved18 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyCurated CoreFDAstaleRocheApproved

bevacizumab (Avastin)

US label: colorectal, non-squamous NSCLC, glioblastoma, renal, cervical and ovarian cancers; regimen-specific indicatio… · VEGF-A

#VEGF-A#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1444Status Approved
AntibodyCurated CoreFDAstaleEli LillyApproved

cetuximab (Erbitux)

US label: head and neck squamous cell cancer and biomarker-selected colorectal cancer; regimen-specific indications · EGFR

#EGFR#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 942Status Approved
AntibodyCurated CoreFDAstaleAstraZenecaApproved

durvalumab (Imfinzi, MEDI4736)

NSCLC (Stage III consolidation), SCLC, biliary tract, HCC · PD-L1

#PD-L1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 750Status Approved
AntibodyCurated CoreFDAstaleRocheApproved

atezolizumab (Tecentriq, MPDL3280A)

NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others · PD-L1

#PD-L1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 693Status Approved
AntibodyCurated CoreFDAstaleAbbVieApproved

adalimumab (Humira, Hyrimoz, Amjevita)

Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA · TNF-α

#TNF-#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 574Status Approved
AntibodyCurated CoreFDAstaleJanssenApproved

daratumumab (Darzalex)

Multiple myeloma · CD38

#CD38#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 454Status Approved
AntibodyCurated CoreFDAstaleBeOne MedicinesApproved

tislelizumab (Tevimbra, BGB-A317, tislelizumab-jsgr)

Esophageal squamous cell carcinoma, gastric/GEJ adenocarcinoma, and first-line HER2-positive GEA with zanidatamab and c… · PD-1

#PD-1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 213Status Approved
AntibodyCurated CoreFDAstaleSanofiApproved

alirocumab (Praluent, REGN727, SAR236553)

Hyperlipidemia, ASCVD, HeFH · PCSK9

#PCSK9#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 103Status Approved
AntibodyCurated CoreFDAstaleUCBApproved

bimekizumab (Bimzelx, UCB4940, bimekizumab-bkzx)

Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa · IL-17A / IL-17F

#IL-17AIL-17F#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 58Status Approved
AntibodyCurated CoreFDAstaleRocheApproved

faricimab (Vabysmo, RG7716, faricimab-svoa)

Wet AMD, diabetic macular edema, macular edema following retinal vein occlusion · Ang-2 / VEGF-A

#Ang-2VEGF-A#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 53Status Approved
AntibodyCurated CoreFDAstaleargenxApproved

efgartigimod (Vyvgart, ARGX-113, Vyvgart Hytrulo, efgartigimod alfa-fcab)

Generalized myasthenia gravis (AChR antibody positive), chronic inflammatory demyelinating polyneuropathy · FcRn (neonatal Fc receptor)

#FcRnneonatalFcreceptor#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 48Status Approved
AntibodyCurated CoreFDAstaleAstraZenecaApproved

tezepelumab (Tezspire, AMG 157, MEDI9929, tezepelumab-ekko)

Severe asthma add-on maintenance, chronic rhinosinusitis with nasal polyps · TSLP (thymic stromal lymphopoietin)

#TSLPthymicstromallymphopoietin#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 47Status Approved
AntibodyCurated CoreFDAstaleAmgenApproved

tarlatamab (Imdelltra, AMG 757, tarlatamab-dlle)

Extensive-stage small cell lung cancer after platinum-based chemotherapy · DLL3 × CD3

#DLL3CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+4
Trials 39Status Approved
AntibodyCurated CoreFDAstaleEisaiApproved

lecanemab (Leqembi, BAN2401, lecanemab-irmb)

Early symptomatic Alzheimer's disease (MCI or mild dementia) with confirmed amyloid pathology · Amyloid-beta protofibrils

#Amyloid-betaprotofibrils#Antibody#Approved#FDA-approved#BioJungboMoa-pick+4
Trials 37Status Approved
AntibodyCurated CoreFDAstaleJazz PharmaceuticalsApproved

zanidatamab (Ziihera, ZW25, zanidatamab-hrii)

First-line HER2-positive gastric, GEJ, or esophageal adenocarcinoma; previously treated HER2-positive biliary tract can… · HER2 (biparatopic)

#HER2biparatopic#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 35Status Approved
AntibodyCurated CoreFDAstaleJohnson & JohnsonApproved

nipocalimab (Imaavy, M281, nipocalimab-aahu)

Generalized myasthenia gravis (AChR or MuSK antibody-positive, age ≥12); warm autoimmune hemolytic anemia · FcRn

#FcRn#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 27Status Approved
AntibodyCurated CoreFDAstaleAstellasApproved

zolbetuximab (Vyloy, IMAB362, zolbetuximab-clzb, claudiximab)

CLDN18.2-positive HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma · CLDN18.2 (claudin-18.2)

#CLDN182claudin-182#Antibody#Approved#FDA-approved#BioJungboMoa-pick+4
Trials 26Status Approved
AntibodyCurated CoreFDAstaleEli LillyApproved

donanemab (Kisunla, LY3002813, donanemab-azbt)

Early symptomatic Alzheimer's disease with confirmed amyloid pathology · N3pG amyloid-beta plaque

#N3pGamyloid-betaplaque#Antibody#Approved#FDA-approved#BioJungboMoa-pick+4
Trials 21Status Approved